|
Clinical efficacy
|
| Rate parameter for PFSa
|
0.045
|
| Shape parameter for OSb
|
2.110
|
| Scale parameter for OSb
|
52.278
|
| Overall response ratec
|
28.74%
|
| Rate parameter for TTDd
|
0.042
|
| Hazard ratio for PFS |
0.524 (0.407, 0.676)
|
0.580 (0.460, 0.720)
|
| Hazard ratio for TTD |
- |
1.000 (0.730, 1.390)
|
| Hazard ratio for OS |
0.682 (0.456, 1.021)
|
0.813 (0.492, 1.345)
|
| Odds ratio for ORe
|
1.420 (1.200, 1.66)
|
1.230 (1.030, 1.440)
|
|
Costs (mean monthly)
|
| Drug acquisition |
£2 950/£1 967/£983
|
£2 950
|
|
Healthcare resource usef
|
PF
|
PD
|
| Healthcare professional visits |
£255
|
£302
|
| Hospitalization |
£147
|
£1 031
|
| Monitoring |
£1
|
£3
|
| Imaging |
£41
|
£49
|
| Total |
£445
|
£1 384
|
|
Subsequent therapy costsg
|
| Second line (endocrine) |
£6579
|
| Second line (chemotherapy) |
£1285
|
| Third line (endocrine) |
£7499
|
| Third line (chemotherapy) |
£1716
|
| Total cost of subsequent therapies |
£5823
|
| Monthly subsequent therapy |
£284
|
|
Utility values
|
| Progression-free (response) |
0.8345 (0.0068)
|
| Progression-free (SD) |
0.8296 (0.0063)
|
| Progressed-disease |
0.5050 (0.0443)
|